Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Summary

The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.

Timeline

Start

2010-11

Primary completion

2011-08

Completion

2012-05

Outcome

Outcome not reported

Stopped (Enrollment): “The study was cancelled by the sponsor prior to initiation of study enrollment. No subjects were accrued.”

Drugs

Indications